Regeneron Pharmaceuticals

Health Care Biotechnology Tarrytown, New York Last filing Feb 4, 2026 · FY2025

                    Revenue
                    FY2025
                
Not reported
                    
                    No matching line (4 accounts checked)
                    
                    Net income
                    FY2025
                
Not reported
                    
                    No matching line (4 accounts checked)
                    
                    Total assets
                    FY2025
                
$40.6B
                    
                    +7.4%
                    
                    Operating cash flow
                    FY2025
                
$5.0B
                    
                    +12.6%

18 yrs · FY2008–FY2025 6 filed · 0 derived · 3 blank

1Y 3Y 5Y 10Y

Dollars % of revenue % of assets YoY % CAGR

Balance Sheet

Assets, liabilities, and equity

28 accounts · 5 years

Total assets $40.6B

Total liabilities $9.3B

Shareholders equity $31.3B

Account	2025	2024	2023	2022	2021
Assets
Cash and Cash Equivalents	$3.1B 25.3%	$2.5B -8.9%	$2.7B -12.1%	$3.1B 7.6%	$2.9B
Short Term Investments	$5.5B -15.9%	$6.5B -19.6%	$8.1B 75.0%	$4.6B 65.0%	$2.8B
Accounts Receivable	$5.7B -7.6%	$6.2B 9.6%	$5.7B 6.4%	$5.3B -11.7%	$6.0B
Inventory	$3.2B 3.7%	$3.1B 19.6%	$2.6B 7.4%	$2.4B 23.1%	$2.0B
Prepaid Expenses	$474.8M 36.0%	$349.2M -9.7%	$386.6M -6.0%	$411.2M 23.7%	$332.4M
Total Current Assets	$18.0B -3.4%	$18.7B -4.2%	$19.5B 22.6%	$15.9B 13.3%	$14.0B
Property,Plant and Equipment	$5.1B 11.3%	$4.6B 10.9%	$4.1B 10.2%	$3.8B 8.1%	$3.5B
Intangible Assets	$1.3B 9.5%	$1.1B 10.6%	$1.0B 13.4%	$915.5M 13564.2%	$6.7M
Long Term Investments	$10.3B 15.3%	$8.9B 64.9%	$5.4B -18.1%	$6.6B -3.6%	$6.8B
Deferred Tax Assets	$4.1B 23.0%	$3.3B 28.7%	$2.6B 49.4%	$1.7B 96.6%	$876.9M
Other Noncurrent Assets	$1.8B 60.3%	$1.1B 155.8%	$444.1M 32.0%	$336.4M 55.7%	$216.1M
Total Assets	$40.6B 7.4%	$37.8B 14.1%	$33.1B 13.2%	$29.2B 14.9%	$25.4B
Liabilities
Accounts Payable	$939.0M 18.9%	$789.5M 30.2%	$606.6M 3.0%	$589.2M 4.5%	$564.0M
Accrued Liabilities	$2.9B 13.8%	$2.5B 7.2%	$2.4B 13.7%	$2.1B -6.0%	$2.2B
Deferred Revenue	$553.0M -11.9%	$627.7M 36.8%	$458.9M -4.0%	$477.9M 8.1%	$442.0M
Total Current Liabilities	$4.4B 10.8%	$3.9B 15.2%	$3.4B 9.0%	$3.1B -20.1%	$3.9B
Long Term Debt	$2.0B 0.1%	$2.0B 0.1%	$2.0B 0.1%	$2.0B 0.1%	$2.0B
Deferred Revenue Noncurrent	$208.7M 12.4%	$185.7M 46.6%	$126.7M 81.5%	$69.8M -4.8%	$73.3M
Operating Lease Liabilities Noncurrent	$720.0M 0.0%	$720.0M 0.0%	$720.0M 0.0%	$720.0M	$0
Other Noncurrent Liabilities	$2.0B 28.5%	$1.6B 84.0%	$854.1M 33.9%	$638.0M -6.2%	$680.2M
Total Liabilities	$9.3B 10.7%	$8.4B 18.3%	$7.1B 8.5%	$6.6B -1.7%	$6.7B
Equity
Preferred Stock	$0	$0	$0	$0	$0
Additional Paid In Capital	$14.0B 8.9%	$12.9B 13.2%	$11.4B 14.1%	$9.9B 23.0%	$8.1B
Retained Earnings	$35.8B 13.0%	$31.7B 16.2%	$27.3B 17.0%	$23.3B 22.9%	$19.0B
Treasury Stock	$18.6B 22.7%	$15.2B 20.8%	$12.6B 21.3%	$10.4B 25.3%	$8.3B
Accumulated Other Comprehensive Income	$77.5M 1081.0%	$-7.9M 90.2%	$-80.9M 66.1%	$-238.8M -811.5%	$-26.2M
Total Stockholders Equity	$31.3B 6.5%	$29.4B 13.0%	$26.0B 14.6%	$22.7B 20.8%	$18.8B
Total Liabilitiesand Equity	$40.6B 7.4%	$37.8B 14.1%	$33.1B 13.2%	$29.2B 14.9%	$25.4B

Income Statement

Revenue, expense, and profitability

4 accounts · 5 years

Revenue Not reported

Operating income Not reported

Net income Not reported

Account	2025	2024	2023	2022	2021
IncomeStatement
net Income Comprehensive Income	$4.6B 2.3%	$4.5B 9.1%	$4.1B -0.3%	$4.1B -48.6%	$8.0B
Earnings Per Share Basic Eps	$43 5.3%	$41 10.4%	$37 -8.5%	$41 -47.0%	$76
Earnings Per Share Diluted Eps	$41 8.2%	$38 10.3%	$35 -9.0%	$38 -46.9%	$72
Earnings Per Share Weighted Average Shares Diluted	$108.6M -5.6%	$115.1M 1.2%	$113.7M 0.2%	$113.5M 1.2%	$112.2M

Cash Flow Statement

Operating, investing, and financing flows

21 accounts · 5 years

Operating cash flow $5.0B

Investing cash flow $-629.1M

Financing cash flow $-3.7B

Account	2025	2024	2023	2022	2021
CashFlow
Operating Activities net Income	$4.5B 2.1%	$4.4B 11.6%	$4.0B -8.9%	$4.3B -46.3%	$8.1B
Operating Activities Depreciation and Amortization	$543.7M 12.6%	$482.9M 14.7%	$421.0M 23.3%	$341.4M 19.3%	$286.2M
Operating Activities Stock Based Compensation	$993.7M 1.1%	$982.8M 11.1%	$885.0M 22.1%	$725.0M 20.5%	$601.7M
Operating Activities Deferred Income Taxes	$-785.4M -3.7%	$-757.3M 9.6%	$-837.8M -12.2%	$-746.4M -407.4%	$-147.1M
Operating Activities Changes In Operating Assets and Liabilities	$532.6M 186.1%	$-618.3M -557.1%	$-94.1M 61.3%	$-243.3M 87.3%	$-1.9B
Operating Activities Other Non Cash Items	$-810.6M -886.1%	$-82.2M -130.9%	$266.3M -55.6%	$599.8M 230.1%	$181.7M
Operating Activities net Cash From Operating Activities	$5.0B 12.6%	$4.4B -3.8%	$4.6B -8.4%	$5.0B -29.2%	$7.1B
Investing Activities Capital Expenditures	$-898.4M -18.9%	$-755.9M -5.2%	$-718.6M -21.8%	$-590.1M -6.9%	$-551.9M
Investing Activities Business Acquisitions	$-3.3M 80.0%	$-16.5M 69.9%	$-54.9M 76.2%	$-230.3M	$0
Investing Activities Purchases of Investments	$-11.0B 34.1%	$-16.6B -42.7%	$-11.6B -55.5%	$-7.5B -6.2%	$-7.0B
Investing Activities Proceeds From Sale of Investments	$11.5B -23.2%	$15.0B 59.2%	$9.4B 70.1%	$5.6B 150.6%	$2.2B
Investing Activities Other Investing Activities	$-315.3M -198.6%	$-105.6M 49.2%	$-207.8M 79.8%	$-1.0B	$0
Investing Activities net Cash From Investing Activities	$-629.1M 74.5%	$-2.5B 22.5%	$-3.2B 15.8%	$-3.8B 29.7%	$-5.4B
Financing Activities Repurchase of Common Stock	$-3.4B -32.1%	$-2.6B -16.5%	$-2.2B -7.3%	$-2.1B -26.6%	$-1.6B
Financing Activities Dividends Paid	$-370.3M	$0	$0	—	—
Financing Activities Proceeds From Stock Issuance	$635.9M -56.6%	$1.5B 27.9%	$1.1B -24.6%	$1.5B -9.1%	$1.7B
Financing Activities Tax Withholding On Stock Based Compensation	$-532.1M 48.3%	$-1.0B -46.9%	$-700.6M -57.2%	$-445.7M 56.8%	$-1.0B
Financing Activities Other Financing Activities	$-10.3M 69.2%	$-33.4M	$0	$0	—
Financing Activities net Cash From Financing Activities	$-3.7B -68.8%	$-2.2B -22.9%	$-1.8B -77.4%	$-1.0B -0.3%	$-1.0B
Cash Reconciliation Effect of Exchange Rate On Cash	$300.0K 142.9%	$-700.0K -75.0%	$-400.0K	$0	$0
Cash Reconciliation net Change In Cash	$634.7M 355.1%	$-248.8M 34.8%	$-381.6M -272.4%	$221.3M -68.0%	$690.8M

Key Ratios

Margins, returns, liquidity, leverage, efficiency

Computed at import · 5 years

Ratio	2025	2024	2023	2022	2021
Profitability
Gross margin	—	—	—	—	—
Operating margin	—	—	—	—	—
Net margin	—	—	—	—	—
FCF margin	—	—	—	—	—
Growth
Revenue CAGR (3y)	—	—	—	—	—
Returns
ROE	—	—	—	—	—
ROA	—	—	—	—	—
ROIC	—	—	—	—	—
Liquidity
Current ratio	4.13x	4.73x	5.69x	5.06x	3.56x
Quick ratio	2.03x	2.21x	2.45x	2.69x	2.27x
Leverage
D/E	0.30x	0.29x	0.27x	0.29x	0.36x
Interest coverage	—	—	—	—	—
Efficiency
Asset turnover	—	—	—	—	—
Cash conversion cycle	—	—	—	—	—

Valuation

Price against fundamentals

FY2025 fundamentals · no price

No price data cached, so there is nothing to multiply. Load prices from the Stock Data tab and this panel reprices itself.

Notes

Your annotations

Not watched

Regeneron Pharmaceuticals

Assets, liabilities, and equity

Revenue, expense, and profitability

Operating, investing, and financing flows

Margins, returns, liquidity, leverage, efficiency

Price against fundamentals

Your annotations

One-year price and volume history

Price data unavailable

Assets, liabilities, and equity

Revenue, expense, and profitability

Operating, investing, and financing flows

Margins, returns, liquidity, leverage, efficiency

Price against fundamentals

Your annotations

One-year price and volume history

Price data unavailable

Recent price history